How GlaxoSmithKline chief has changed the agenda for big pharma - • Shift in expectations over health in developing world • Critics say GSK hopes for profits in future years Few who hear him doubt Andrew Witty's desire to improve health in the developing world is sincere.

"Silent pandemic" will force drug price rethink - LONDON (Reuters) - A "silent pandemic" of chronic disease is creeping up on poor countries and will force pharmaceutical firms to take a more tiered approach to pricing some of their most lucrative medicines.

Global pill price 'snapshot' reveals large differences in the price of ciprofloxacin - Global pill price 'snapshot' reveals large differences in the price of ciprofloxacin On 30 November 2009 Health Action International (HAI) undertook a global "snapshot" of the price of ciprofloxacin, a commonly used off-patent antibiotic. Individuals from HAI's extended network and partners visited

LEVALBUTEROL HYDROCHLORIDEinhalant [Mylan Pharmaceuticals Inc.] - Updated Date: Jan 15, 2010 EST [DailyMed]

ALOPRIM (Allopurinol) Injection, Powder, Lyophilized, For Solution [Bioniche Pharma USA LLC] - Updated Date: Jan 15, 2010 EST [DailyMed]

A Model to Improve Quality of Medication Use Among Older Patients: An Expert Interview With Mary T. Roth, PharmD, MHS - Even after controlling for nonadherence, black patients had more medication-related problems than whites and poorer quality of medication use. Medscape Medical News [MEDSCAPE]

AZATHIOPRINEtablet [Mylan Pharmaceuticals Inc.] - Updated Date: Dec 22, 2009 EST [DailyMed]

OXISTAT (Oxiconazole Nitrate) Lotion [Rebel Distributors Corp.] - Updated Date: Dec 22, 2009 EST [DailyMed]

SODIUM CHLORIDEirrigant [Baxter Healthcare Corporation] - Updated Date: Dec 22, 2009 EST [DailyMed]

HYDROCODONE BITARTRATE AND ACETAMINOPHENtablet [UDL Laboratories, Inc.] - Updated Date: Dec 22, 2009 EST [DailyMed]

BAR: AIDS advocates worry drug program will be cut (AEGiS.org) - AIDS advocates worry drug program will be cut
Bay Area Reporter - December 3, 2009
Seth Hemmelgarn, s.hemmelgarn@ebar.com

Global Update: AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease (AEGiS.org) - Global Update: AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease
The New York Times - November 10, 2009 Donald G. Mcneil Jr.
http://www.aegis.org/news/nyt/2009/NYT091108.html

Pfizer's Selzentry Poised To Be Most Expensive First-Line AIDS Drug (AEGiS.org) - Pfizer's Selzentry Poised To Be Most Expensive First-Line AIDS Drug
Business Wire - October 08, 2009
http://www.aegis.org/news/bw/2009/BW091011.html

FDA Marks 100th HIV/AIDS Drug Authorized for Purchase Under PEPFAR (AEGiS.org) - FDA Marks 100th HIV/AIDS Drug Authorized for Purchase Under PEPFAR
Business Wire - October 06, 2009
http://www.aegis.org/news/bw/2009/BW091004.html

FDA sees no safety issues with Pfizer HIV drug (AEGiS) -
FDA sees no safety issues with Pfizer HIV drug
Associated Press - October 6, 2009 Matthew Perrone, AP Business Writer
http://www.aegis.org/news/ap/2009/AP091005.html

Cheap drugs could cut deaths in childbirth in Africa, say researchers - The lives of a third of the women who die in childbirth could be saved if a cheap and common drug to prevent haemorrhage, together with antibiotics, were readily available in their villages, according to a paper published in one of the world's top medical journals, the Lancet.

Africa: Text messages highlight drug stock-outs (AEGiS) -
Africa: Text messages highlight drug stock-outs
Integrated Regional Information Networks - September 17, 2009
http://www.aegis.org/news/irin/2009/IR090925.html 

Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV: Multiple-doses up to 200 mg once-daily well tolerated (AEGiS) -
Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV: Multiple-doses up to 200 mg once-daily well tolerated
PRNewswire - September 14, 2009

GlaxoSmithKline urged to pool its patents on HIV drugs - guardian.co.uk -

India rejects ARV patent applications, saving "countless lives" - NAIROBI - AIDS activists have praised a decision by the Indian patent office to reject patent applications for two life-prolonging antiretroviral (ARV) drugs, allowing Indian manufacturers to keep on making and exporting generic versions.